Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,005 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: First Line Therapy Clear all
Completed Phase 2 Interventional Results available

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

NCT02659059
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
29
States / cities
San Diego, California • Plainville, Connecticut • Weston, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

NCT01271504
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Sorafenib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Tucson, Arizona • Fort Myers, Florida • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 2 Interventional

A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

NCT00251485
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Cetuximab
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 20, 2026, 10:04 PM EDT
Terminated Phase 3 Interventional Results available

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

NCT05226598
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer
Interventions
Pembrolizumab/Vibostolimab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
12
States / cities
Colorado Springs, Colorado • Fort Collins, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 2 Interventional

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

NCT01519804
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Placebo, cisplatin/carboplatin, onartuzumab, paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
34
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 20, 2026, 10:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

NCT03830918
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Atezolizumab, Niraparib, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Biological · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

NCT03775486
View directory record Official record
Conditions
Non-small Cell Lung Cancer NSCLC
Interventions
Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Recruiting Phase 2Phase 3 Interventional

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301
View directory record Official record
Conditions
Advanced Melanoma
Interventions
EIK1001, Pembrolizumab (KEYTRUDA® )
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
14
States / cities
Chandler, Arizona • Hot Springs, Arkansas • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

NCT00906373
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg), IMC-A12 (cixutumumab) - 20 mg/kg, Sorafenib
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 20, 2026, 10:04 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

NCT06173505
View directory record Official record
Conditions
Nonsquamous Non-small Cell Lung Cancer
Interventions
Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Combination Product
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Glendale, Arizona • Norwich, Connecticut • Fredericksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Active, not recruiting Phase 3 Interventional

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

NCT02446405
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Enzalutamide, NSAA, LHRHA or Surgical Castration
Drug
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 20, 2026, 10:04 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

NCT03003962
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma NSCLC
Interventions
Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

NCT00075270
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Paclitaxel, GW572016 (Lapatinib)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
45
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 3 Interventional

Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)

NCT00087802
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
gemcitabine/Eloxatin (GEMOX), carboplatin/paclitaxel (CP)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
70
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2009 · Synced Oct 20, 2026, 10:04 PM EDT
Terminated No phase listed Observational

Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients

NCT01076751
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
Male only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 14, 2011 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

NCT02551159
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
MEDI4736, Tremelimumab, MEDI4736+Tremelimumab, Cetuximab, 5-fluorouracil (5FU), Cisplatin, Carboplatin
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
19
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Fort Myers, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 20, 2026, 10:04 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT07216703
View directory record Official record
Conditions
Cervical Cancer
Interventions
Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab, Paclitaxel, Cisplatin, Carboplatin, Rescue Medications
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
30
States / cities
Birmingham, Alabama • Anchorage, Alaska • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Not listed Phase 2 Interventional

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

NCT01609127
View directory record Official record
Conditions
Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer
Interventions
Tesetaxel, Capecitabine
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older · Female only
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 20, 2026, 10:04 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)

NCT01757197
View directory record Official record
Conditions
Glucocorticosteroid Refractory Acute GVHD
Interventions
Toclizumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 20, 2026, 10:04 PM EDT
Terminated Phase 3 Interventional Results available

Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

NCT03348904
View directory record Official record
Conditions
Lung Cancer
Interventions
Nivolumab, Epacadostat, Placebo, Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Anaheim, California • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer

NCT00867321
View directory record Official record
Conditions
Liver Cancer
Interventions
bevacizumab, sorafenib tosylate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
177
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 113 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 20, 2026, 10:04 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

NCT01126749
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine, E7389, Cisplatin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 20, 2026, 10:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

NCT05445843
View directory record Official record
Conditions
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Interventions
JDQ443
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

NCT02711553
View directory record Official record
Conditions
Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
Interventions
Ramucirumab, Merestinib, Cisplatin, Gemcitabine, Placebo Oral, Placebo IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 20, 2026, 10:04 PM EDT